
Rob Boyce discusses the mission of Plakous Therapeutics to develop treatments for necrotizing enterocolitis in premature infants.
This episode is part of a limited series called Money Ball in conjunction with the BLPN Club . BLPN's Money Ball program helps founders step up to the plate and knock fundraising out of the park. You'll hear about the people, their ventures, and their pitch-making experiences. In this episode, Rob Boyce, CEO of Plakous Therapeutics, discusses the company's mission to develop regenerative medicine solutions for necrotizing enterocolitis (NEC), a devastating disease affecting premature infants. He shares insights into the challenges of developing treatments for this vulnerable population, the importance of funding, and the role of networking in the biotech industry. Rob also highlights a case study of a patient named Laurel, illustrating the potential impact of their product on improving outcomes for babies at risk of NEC. Chapters: 00:00 Introduction to Plakous Therapeutics 01:08 Understanding Necrotizing Enterocolitis (NEC) 04:23 The Genesis of Plakous Therapeutics 06:24 Innovative Approach to Treatment 09:27 Real-Life Impact: Case Study of Laurel 13:32 Navigating the Funding Landscape 16:06 Refining the Pitch Process 22:05 Challenges in the Current Investment Climate 25:11…
Host: Heath Fletcher
Guest: Robert Boyce
Organizations: Plakous Therapeutics
Products: regenerative medicine solutions
Places: necrotizing enterocolitis
Explore listener stats, chart rankings, contacts and more on the The Healthy Enterprise podcast page.